The biotech’s initial JANX011 Phase 1 results in healthy volunteers triggered a sharp selloff as investors questioned near-term value and differentiation.
Wolfe Research upgrades Janux Therapeutics to Outperform with a $23 target. Q4 autoimmune data for JANX011 cited as key catalyst, 32% upside.
Barclays cut Janux Therapeutics to Underweight, citing doubts on JANX007 and limited near-term upside despite long-term potential.
Janux Therapeutics announces collaboration with Bristol Myers Squibb to develop novel tumor-activated cancer therapy, with potential payments up to $850 million.
Janux Therapeutics' (JANX) JANX007 immunotherapy disappoints with only 30% response rate in heavily pre-treated prostate cancer patients, raising concerns about efficacy.
